Claims for Patent: 5,804,410

Summary for Patent: 5,804,410

Title:	Nucleic acid sequence encoding trypsin-like enzyme and process for producing the enzyme
Abstract:	This invention provides a nucleic acid sequence encoding a trypsin-like enzyme which can be present at the trachea of human lungs, and can selectively digest a synthetic substrate for trypsin and a synthetic substrate for thrombin, and fibrinogen; and a process for producing the trypsin-like enzyme by genetic engineering utilizing the nucleic acid sequence.
Inventor(s):	Yamaoka; Kazuyoshi (Hino, JP), Ogawa; Hiroko (Hino, JP), Sugimoto; Yoshinori (Hino, JP), Masuda; Kenichi (Hino, JP), Suga; Tetsuya (Hino, JP), Takagi; Kenichiro (Hino, JP), Yasuoka; Susumu (Tokushima, JP)
Assignee:	Teijin Limited (Osaka, JP)
Application Number:	08/508,448
Patent Claims:	1. A nucleic acid sequence encoding a trypsin-like enzyme having the following amino acid sequence: ##STR3## 2. The nucleic acid sequence according to claim 1 has the following sequence: ##STR4## 3. The nucleic acid sequence of claim 2, having the DNA sequence depicted in SEQ ID NO. 24. 4. A recombinant expression vector comprising the nucleic acid of claim 1 or claim 3. 5. A host cell transformed with the expression vector of claim 4. 6. A process for producing a trypsin-like enzyme having the amino acid sequence according to SEQ ID NO. 19, comprising culturing a transformed host according to claim 5, and recovering the trypsin-like enzyme from said culture. 7. A purified trypsin-like enzyme having the amino acid sequence set forth in SEQ ID NO. 19. 8. A purified prepro-trypsin-like enzyme having the amino acid sequence set forth in SEQ ID NO. 25. 9. A purified trypsin-like enzyme obtained from phlegm, said trypsin-like enzyme having a molecular weight of 28 kD on SDS-PAGE and having the following activities: a) digests synthetic substrates for trypsin or for thrombin, said substrates selected from the group consisting of Boc-Phe-Ser-Arg-methylcoumarinamide (MCA), Boc-Gln-Ala-Arg-MCA, and Boc-Val-Pro-Arg-MCA, b) does not digest synthetic substrates for chymotrypsin, elastase, collagenase, or for leucine aminopeptidase, c) is inactivated at pH 6.0, d) is inhibited by diisopropyl fluorophosphate (DFP), phenylmethylsulfonyl fluoride (PMSF), leupeptin, and antipain, and e) inactivates influenza viruses.

Details for Patent 5,804,410

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Smith & Nephew, Inc.	SANTYL	collagenase	Ointment	101995	06/04/1965		2014-07-29